M&A Deal Summary

ANI Pharmaceuticals Acquires Noven Therapeutics - NDA Lithobid

On July 1, 2014, ANI Pharmaceuticals acquired life science company Noven Therapeutics - NDA Lithobid from Noven Pharmaceuticals for 12M USD

Acquisition Highlights
  • This is ANI Pharmaceuticals’ 4th transaction in the Life Science sector.
  • This is ANI Pharmaceuticals’ 7th largest (disclosed) transaction.
  • This is ANI Pharmaceuticals’ 4th transaction in the United States.

M&A Deal Summary
Date 2014-07-01
Target Noven Therapeutics - NDA Lithobid
Sector Life Science
Buyer(s) ANI Pharmaceuticals
Sellers(s) Noven Pharmaceuticals
Deal Type Divestiture
Deal Value 12M USD

Target

Noven Therapeutics - NDA Lithobid

United States
Noven Therapeutics - NDA Lithobid comprises the pharmaceutical preparation Lithobid, a 300 mg tablet with lithium carbonate extended release.

Search 198,123 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ANI Pharmaceuticals

Baudette, Minnesota, United States
Category Company
Founded 2001
Sector Life Science
Employees369
Revenue 208M USD (2020)
DESCRIPTION

ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI has several ANDAs pending FDA approval and in various stages of development. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.

DEAL STATS #
Overall 4 of 15
Sector (Life Science) 4 of 13
Type (Divestiture) 3 of 11
Country (United States) 4 of 12
Year (2014) 1 of 1
Size (of disclosed) 7 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-12-26 Teva Pharmaceutical - 31 Generic Drug Products

United States

Teva Pharmaceutical - 31 Generic Drug Products includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products.

Buy $13M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-03-05 Teva Pharmaceutical Industries - Flecainide Tablets USP

Israel

Flecainide acetate is an antiarrhythmic drug indicated for use in patients without structural heart disease for the prevention of paroxysmal supraventricular tachycardias (PSVT), including atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms as well as paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Flecainide acetate tablets USP are also indicated for the prevention of documented ventricular arrhythmias, such as sustained ventricular tachycardia (sustained VT), that in the judgment of the physician are life-threatening.

Buy -

Seller(S) 1

SELLER

Noven Pharmaceuticals

Miami, Florida, United States
Category Company
Founded 1987
Sector Life Science
Employees650
DESCRIPTION

Noven Pharmaceuticals, Inc. pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2014) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2007-07-10 JDS Pharmaceuticals

Morrisville, Pennsylvania, United States

JDS is a pharmaceutical company focused on the central nervous system. The company sold Pexeva and Lithobid® through its specialty salesforce, and had a pipeline of products in clinical development.

Buy $187M
Mergr

Product

Company

Legal